vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and AdvanSix Inc. (ASIX). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $284.0M, roughly 1.3× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -0.8%, a 97.1% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 3.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
ACAD vs ASIX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $359.9M |
| Net Profit | $273.6M | $-2.8M |
| Gross Margin | 90.8% | 7.6% |
| Operating Margin | 6.1% | -0.7% |
| Net Margin | 96.3% | -0.8% |
| Revenue YoY | 9.4% | 9.4% |
| Net Profit YoY | 90.3% | -892.9% |
| EPS (diluted) | $1.61 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $359.9M | ||
| Q3 25 | $278.6M | $374.5M | ||
| Q2 25 | $264.6M | $410.0M | ||
| Q1 25 | $244.3M | $377.8M | ||
| Q4 24 | $259.6M | $329.1M | ||
| Q3 24 | $250.4M | $398.2M | ||
| Q2 24 | $242.0M | $453.5M | ||
| Q1 24 | $205.8M | $336.8M |
| Q4 25 | $273.6M | $-2.8M | ||
| Q3 25 | $71.8M | $-2.6M | ||
| Q2 25 | $26.7M | $31.4M | ||
| Q1 25 | $19.0M | $23.3M | ||
| Q4 24 | $143.7M | $352.0K | ||
| Q3 24 | $32.8M | $22.3M | ||
| Q2 24 | $33.4M | $38.9M | ||
| Q1 24 | $16.6M | $-17.4M |
| Q4 25 | 90.8% | 7.6% | ||
| Q3 25 | 92.2% | 6.8% | ||
| Q2 25 | 92.2% | 14.3% | ||
| Q1 25 | 91.7% | 14.2% | ||
| Q4 24 | 91.6% | 3.4% | ||
| Q3 24 | 92.5% | 14.4% | ||
| Q2 24 | 92.5% | 17.9% | ||
| Q1 24 | 88.8% | 0.9% |
| Q4 25 | 6.1% | -0.7% | ||
| Q3 25 | 12.8% | -0.9% | ||
| Q2 25 | 12.2% | 7.7% | ||
| Q1 25 | 7.9% | 7.7% | ||
| Q4 24 | 59.1% | -3.9% | ||
| Q3 24 | 12.6% | 7.5% | ||
| Q2 24 | 12.6% | 11.5% | ||
| Q1 24 | 7.4% | -7.0% |
| Q4 25 | 96.3% | -0.8% | ||
| Q3 25 | 25.8% | -0.7% | ||
| Q2 25 | 10.1% | 7.7% | ||
| Q1 25 | 7.8% | 6.2% | ||
| Q4 24 | 55.4% | 0.1% | ||
| Q3 24 | 13.1% | 5.6% | ||
| Q2 24 | 13.8% | 8.6% | ||
| Q1 24 | 8.0% | -5.2% |
| Q4 25 | $1.61 | $-0.11 | ||
| Q3 25 | $0.42 | $-0.10 | ||
| Q2 25 | $0.16 | $1.15 | ||
| Q1 25 | $0.11 | $0.86 | ||
| Q4 24 | $0.86 | $0.02 | ||
| Q3 24 | $0.20 | $0.82 | ||
| Q2 24 | $0.20 | $1.43 | ||
| Q1 24 | $0.10 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $19.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $815.2M |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $19.8M | ||
| Q3 25 | $258.0M | $23.7M | ||
| Q2 25 | $253.6M | $18.4M | ||
| Q1 25 | $217.7M | $8.3M | ||
| Q4 24 | $319.6M | $19.6M | ||
| Q3 24 | $155.1M | $17.3M | ||
| Q2 24 | $177.1M | $12.1M | ||
| Q1 24 | $204.7M | $20.6M |
| Q4 25 | $1.2B | $815.2M | ||
| Q3 25 | $917.3M | $818.2M | ||
| Q2 25 | $822.4M | $823.7M | ||
| Q1 25 | $765.2M | $794.4M | ||
| Q4 24 | $732.8M | $774.6M | ||
| Q3 24 | $577.2M | $766.4M | ||
| Q2 24 | $516.7M | $746.6M | ||
| Q1 24 | $464.0M | $713.2M |
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.2B | $1.6B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $976.9M | $1.5B | ||
| Q2 24 | $914.1M | $1.5B | ||
| Q1 24 | $855.1M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $63.7M |
| Free Cash FlowOCF − Capex | — | $36.1M |
| FCF MarginFCF / Revenue | — | 10.0% |
| Capex IntensityCapex / Revenue | — | 7.7% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $6.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $63.7M | ||
| Q3 25 | $74.3M | $26.6M | ||
| Q2 25 | $64.0M | $21.1M | ||
| Q1 25 | $20.3M | $11.4M | ||
| Q4 24 | $40.4M | $64.2M | ||
| Q3 24 | $63.2M | $57.3M | ||
| Q2 24 | $25.0M | $50.2M | ||
| Q1 24 | $29.1M | $-36.2M |
| Q4 25 | — | $36.1M | ||
| Q3 25 | $73.9M | $66.0K | ||
| Q2 25 | — | $-7.2M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $29.8M | ||
| Q3 24 | $63.2M | $26.8M | ||
| Q2 24 | — | $16.7M | ||
| Q1 24 | — | $-71.6M |
| Q4 25 | — | 10.0% | ||
| Q3 25 | 26.5% | 0.0% | ||
| Q2 25 | — | -1.7% | ||
| Q1 25 | — | -6.0% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | 25.2% | 6.7% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | -21.3% |
| Q4 25 | — | 7.7% | ||
| Q3 25 | 0.1% | 7.1% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 9.0% | ||
| Q4 24 | — | 10.4% | ||
| Q3 24 | 0.0% | 7.7% | ||
| Q2 24 | — | 7.4% | ||
| Q1 24 | — | 10.5% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 0.67× | ||
| Q1 25 | 1.07× | 0.49× | ||
| Q4 24 | 0.28× | 182.29× | ||
| Q3 24 | 1.93× | 2.57× | ||
| Q2 24 | 0.75× | 1.29× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
